Skinvisible Pharmaceuticals announces 99.6% effective transdermal glucose control without patches or needles in a study.

Skinvisible Pharmaceuticals has published findings on its transdermal delivery system, Invisicare®, which effectively administers glucose-controlling agents without patches or needles. The study showed a remarkable 99.6% delivery rate for GLP-1 formulations over six hours. This method may enhance patient compliance and reduce side effects linked to oral medications. The company seeks partnerships to advance transdermal obesity therapies and explore wider applications of its technology.

October 03, 2024
7 Articles

Further Reading